From Clinical Lab Products: "Measurement of PD-L1 is challenging not only when tissue is lacking, but due to the inherent complexity of immunohistochemistry,” says Pritchett. “The testing approach demonstrated in this study shows promise as a method of assessing PD-L1 in plasma. A more objective measure of PD-L1 status could offer a path to better patient care decisions in the treatment of non-small cell lung cancer.” - Dr. Michael Pritchett. Read more.